These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 26099008)

  • 1. Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers.
    Mackenzie R; Talhouk A; Eshragh S; Lau S; Cheung D; Chow C; Le N; Cook LS; Wilkinson N; McDermott J; Singh N; Kommoss F; Pfisterer J; Huntsman DG; Köbel M; Kommoss S; Gilks CB; Anglesio MS
    Am J Surg Pathol; 2015 Nov; 39(11):1548-57. PubMed ID: 26099008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
    Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
    Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases.
    Köbel M; Meng B; Hoang LN; Almadani N; Li X; Soslow RA; Gilks CB; Lee CH
    Am J Surg Pathol; 2016 Feb; 40(2):166-180. PubMed ID: 26492180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
    Ramalingam P
    Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy.
    Chui MH; Ryan P; Radigan J; Ferguson SE; Pollett A; Aronson M; Semotiuk K; Holter S; Sy K; Kwon JS; Soma A; Singh N; Gallinger S; Shaw P; Arseneau J; Foulkes WD; Gilks CB; Clarke BA
    Am J Surg Pathol; 2014 Sep; 38(9):1173-81. PubMed ID: 25025451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma.
    Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S
    APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histotype-genotype correlation in 36 high-grade endometrial carcinomas.
    Hoang LN; McConechy MK; Köbel M; Han G; Rouzbahman M; Davidson B; Irving J; Ali RH; Leung S; McAlpine JN; Oliva E; Nucci MR; Soslow RA; Huntsman DG; Gilks CB; Lee CH
    Am J Surg Pathol; 2013 Sep; 37(9):1421-32. PubMed ID: 24076778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
    Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
    Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-grade Endometrioid Carcinoma of the Ovary: A Clinicopathologic Study of 30 Cases.
    Assem H; Rambau PF; Lee S; Ogilvie T; Sienko A; Kelemen LE; Köbel M
    Am J Surg Pathol; 2018 Apr; 42(4):534-544. PubMed ID: 29309296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory role of prohibitin in human ovarian epithelial cancer.
    Jia L; Ren JM; Wang YY; Zheng Y; Zhang H; Zhang Q; Kong BH; Zheng WX
    Int J Clin Exp Pathol; 2014; 7(5):2247-55. PubMed ID: 24966933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accurate Distinction of Ovarian Clear Cell From Endometrioid Carcinoma Requires Integration of Phenotype, Immunohistochemical Predictions, and Genotype: Implications for Lynch Syndrome Screening.
    Rodriguez M; Kang EY; Farrington K; Cook LS; Le ND; Karnezis AN; Lee CH; Nelson GS; Terzic T; Lee S; Köbel M
    Am J Surg Pathol; 2021 Nov; 45(11):1452-1463. PubMed ID: 34534137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
    BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
    Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Profiles of Mixed Endometrial Carcinoma.
    Matrai C; Motanagh S; Mirabelli S; Ma L; He B; Chapman-Davis E; Kurtis B; Elemento O; Mosquera JM; Ellenson LH
    Am J Surg Pathol; 2020 Aug; 44(8):1104-1111. PubMed ID: 32604171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression of IMP3 in 366 cases with ovarian carcinoma of high grade serous, endometrioid and clear cell subtypes.
    Lu L; Wang S; Zhu Q; Qu Y; Gu W; Ning Y; Chen X; Wang Y
    Pathol Res Pract; 2018 Aug; 214(8):1087-1094. PubMed ID: 29866423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endometrial Adenocarcinomas With Significant Mucinous Differentiation: A Characterization of Intratumoral Heterogeneity of KRAS Mutations in Mucinous and Endometrioid Histologic Components.
    Jackson CL; Hang S; Hansen K; He M; Sung CJ; Quddus MR; Xiong M; Wang Y; Patel NR; Lawrence WD; Xiong J
    Int J Gynecol Cancer; 2018 Feb; 28(2):241-247. PubMed ID: 29303928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Application Value of HNF-1β Transcription Factor in the Diagnosis of Ovarian Clear Cell Carcinoma.
    Huang W; Cheng X; Ji J; Zhang J; Li Q
    Int J Gynecol Pathol; 2016 Jan; 35(1):66-71. PubMed ID: 26166716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant Expression of Anaplastic Lymphoma Kinase in Ovarian Carcinoma Independent of Gene Rearrangement.
    Tang S; Yang F; Du X; Lu Y; Zhang L; Zhou X
    Int J Gynecol Pathol; 2016 Jul; 35(4):337-47. PubMed ID: 27271776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian carcinoma diagnosis: the clinical impact of 15 years of change.
    Kommoss S; Gilks CB; du Bois A; Kommoss F
    Br J Cancer; 2016 Oct; 115(8):993-999. PubMed ID: 27632374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.